KMDA

Company Expects Growing Biosimilar Product Portfolio, Commercialized in Israel and the MENA Region, to Generate Approximately $10 Million in Annual Revenue in 2028 and Approximately $20 Million-$25 Million in Annual Revenue by 2030 Company Expects Growing Biosimilar Product Portfolio, Commercialized in Israel and the MENA Region, to Generate Approximately $10 Million in Annual Revenue in 2028 and Approximately $20 Million-$25 Million in Annual Revenue by 2030

U.S. Centers for Disease Control and Prevention (CDC) Reports a Significant Year-Over-Year Increase in Nationwide Rabies Exposures and Rabies Immunoglobulin Utilization KedRAB is One of Only Two FDA-Approved Anti-Rabies Immunoglobulin Products in the U.S. Market Estimated at $200 Million Annually Kamada's Manufacturing Capacity and Supply Availability Positioned to Support Increased Demand REHOVOT, Israel, and HOBOKEN, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.

REHOVOT, Israel, and HOBOKEN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate and present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel.

REHOVOT, Israel and HOBOKEN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the “Ruling”) from the Israel Tax Authority (the “ITA”) with respect to the cash dividend of $0.17 (approximately NIS 0.51) per share on the Company's ordinary shares (totaling approximately $9.8 million) announced on August 17, 2026 (the “Dividend”), expected to be paid on September 17, 2026 (the “Payment Date”), to shareholders of record at the close of business on August 27, 2026 (the “Record Date”).

Dividend to be Paid Consistent with the Company's Cash Dividend Policy Dividend to be Paid Consistent with the Company's Cash Dividend Policy

Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Prothena (PRTA). But which of these two companies is the best option for those looking for undervalued stocks?

Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript

Although the revenue and EPS for Kamada (KMDA) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

REHOVOT, Israel and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced financial results for the three months and six months ended June 30, 2026.